Central Obesity, Body Mass Index, Metabolic Syndrome and Mortality in Mediterranean Breast Cancer Patients
Author:
Crispo Anna1, Augustin Livia Silvia1, Luongo Assunta1, Calderaio Claudia2, Breda Joao3, Coluccia Sergio1, Calabrese Alessandra4, Marrazzo Vittorio2, Giannatiempo Rosa5, Trasacco Paola2, Palumbo Elvira1, Vitale Sara1, Porciello Giuseppe1, Gennaro Piergiacomo Di1, Caputo Roberta4, Buono Giuseppe4, Vernieri Claudio6, Schettini Francesco7, Grimaldi Maria1, Nocerino Flavia1, Celentano Egidio1, Amore Alfonso8, Giuliano Mario2, De Placido Pietro2, De Angelis Carmine2, Bianco Roberto2, De Laurentiis Michelino4, Vecchia Carlo La9, Arpino Grazia2
Affiliation:
1. Istituto Nazionale Tumori-IRCCS “Fondazione G. Pascale” 2. University of Naples Federico II 3. WHO Athens Quality of Care Office 4. Istituto Nazionale Tumori - IRCCS, 'Fondazione Pascale' 5. Ospedale Evangelico Betania, Department of Pathology 6. IFOM ETS 7. Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS 8. Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS 9. Università degli Studi di Milano
Abstract
Abstract
Background: Obesity and metabolic disorders have been associated with poorer outcomes in many cohorts
of breast cancer (BC) patients, with poor evidence from Mediterranean cohorts. The purpose of this study is to investigate the prognostic potential of anthropometric variables in early BC patients living in a Southern region of Italy.
Methods: This prospective cohort study enrolled 955 consecutive early BC patients treated at the Istituto Nazionale dei Tumori “G. Pascale” and at the University Hospital “Federico II”, Naples, Italy, between January 2009 and December 2013. Median follow-up was 11.8 years and ended on June 15th 2022. Anthropometric measurements and indices namely body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), as well as Metabolic Syndrome (MetS) and its components, were collected. All-cause and BC-specific mortality were calculated.
Results: Mean age was 55.3 years (±12.5 years); 61% of patients were post-menopausal. At data cut-off, 208 (22%) patients had died, 131 (14%) of whom from BC. Obesity was found in 29% of patients. High WC or WHR and the presence of MetS were associated with a moderately increased risk of all-cause mortality (WC ≥ 88 cm, HR=1.39, 95%CI:1.00-1.94; WHR > 0.85, HR=1.62, 95%CI:1.12-2.37; MetS, HR=1.61, 95%CI:1.12-2.32). An increased BC-specific mortality risk was found in obese patients (HR=1.72, 95%CI:1.06-2.78), in those with WC ≥88 (HR=1.71, 95%CI:1.12-2.61)and in those with high WHR, both when evaluated as a categorical variable (WHR>0.85, HR=1.80, 95%CI:1.13-2.86) and as a continuous variable (for each 0.1-U increase in WHR, HR=1.33, 95%CI:1.08-1.63) as well as the presence of MetS (HR=1.81, 95%CI:1.51-2.85). These associations varied according to menopausal status and BC subtype.
Conclusions: Central obesity significantly increased total and BC-specific mortality particularly in pre-menopausal women, while in post-menopause the MetS was a stronger risk factor. These associations were significant mainly in luminal subtypes while no relevant findings were observed in TNBC. The magnitude of risk suggests that obesity and the presence of the MetS or its single components may nullify the benefit of effective BC therapies. Active lifestyle intervention studies should be encouraged for several expected beneficial effects.
Publisher
Research Square Platform LLC
Reference30 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA: a cancer journal for clinicians,2021 2. Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries;Dafni U;Breast care,2019 3. World Health Organization ROfE: WHO European Regional Obesity Report 2022. World Health Organization. Regional Office for Europe. In.; 2022. 4. Obesity, Body Composition, and Breast Cancer: An Evolving Science;Bandera EV;JAMA oncology,2018 5. Central body fatness is a stronger predictor of cancer risk than overall body size;Barberio AM;Nat Commun,2019
|
|